A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers

A. Bartoli, G. Gatti, G. Cipolla, N. Barzaghi, G. Veliz, C. Fattore, J. Mumford, E. Perucca

Research output: Contribution to journalArticle

Abstract

Purpose: This study was conducted to determine whether vigabatrin affects in vivo indices of hepatic microsomal enzyme activity and the pharmacokinetics of steroid oral contraceptives in healthy subjects. Methods: Under double-blind conditions. 13 female healthy volunteers received, in random order and with a washout interval of ≤4 weeks, two oral 4-week treatments with vigabatrin (VGB) (maintenance dosage, 3,000 mg daily) and placebo, respectively. The clearance and half-life of antipyrine (a broad marker of drug oxidation capacity), the urinary excretion of 6-β- hydroxycortisol (a selective marker of cytochrome CYP3A-mediated oxidation), and the activity of serum γ-glutamyltransferase (a nonspecific index of microsomal enzyme activity) were determined after 3 weeks of each treatment. The single-dose kinetics of a combined oral contraceptive containing 30 μg ethinyl estradiol and 150 μg levonorgestrel were also determined after 3 weeks of treatment by specific radioimmunologic assays. Results: VGB treatment had no influence on antipyrine clearance (28 ± 5.6 vs. 30 ± 4.5 ml/h/kg on placebo), antipyrine half-life (15.5 ± 3.5 vs, 14,1 ± 2.1 h), urinary 6-β-hydroxycortisol excretion (488 ± 164 vs. 470 ± 228 nmol/day), 6-β-hydroxycortisol-to-cortisol concentration ratio (6.8 ± 3.1 vs. 6.1 ± 3.1) and serum γ-glutamyltransferase activity (12 ± 3 vs. 11 ± 3 IU/L). No difference in pharmacokinetic parameters between VGB and placebo sessions were found for ethinyl estradiol (half-life. 12.5 ± 3.2 vs. 13.9 ± 3.2 h; AUC, 874 ± 301 vs. 939 ± 272 ng/L/h) and levonorgestrel (half-life, 17.7 ± 5,2 vs. 23.1 ± 9.8 h; AUC, 27.5 ± 9.6 vs. 30.0 ± 12.0/μg/L/h). Two subjects, however, showed a 50 and a 39% reduction in ethinyl estradiol AUC during VGB treatment. Conclusions: At therapeutic dosages, VGB did not modify in vivo indices of hepatic microsomal enzyme activity and did not interfere significantly with the CYP3A-mediated metabolism of ethinyl estradiol and levonorgestrel. Based on these data, VGB is unlikely to affect consistently the efficacy of steroid oral contraceptives or interact pharmacokinetically with drugs that are eliminated mainly by oxidative pathways, particularly those involving cytochrome CYP3A.

Original languageEnglish
Pages (from-to)702-707
Number of pages6
JournalEpilepsia
Volume38
Issue number6
DOIs
Publication statusPublished - 1997

Keywords

  • 6-β- Hydroxycortisol
  • Antipyrine
  • Contraceptive pill
  • Drug interaction
  • Pharmacokinetics
  • Vigabatrin

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers'. Together they form a unique fingerprint.

  • Cite this